Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 2823 of 5804
-
Could a nasal spray fight Alzheimer's? early trial begins
Disease control CompletedIn this research study investigators aim to learn more about a new drug called Protollin as a possible new treatment for Alzheimer's Disease (AD). The primary goal is to assess the safety and tolerability.
Phase: PHASE1 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Brain scans reveal how mindfulness tames anxiety
Knowledge-focused OngoingThe purpose of this study is to understand the neural mechanisms that drive response to MBSR compared to stress education in patients with generalized anxiety disorder (GAD), and to examine the degree to which sex differences in MBSR response are explained by sex differences in t…
Phase: NA • Sponsor: NYU Langone Health • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
New imaging tracer could reveal if chemo reaches pancreatic cancer
Diagnosis OngoingThe purpose of this study is to find out whether a pre-treatment PET scan using the experimental imaging tracer 18F-FAC can show how much of the standard chemotherapy for PDAC may be taken up by the cancer.
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Jun 26, 2026 13:37 UTC
-
Could a simple iodine solution make thyroid surgery safer?
Disease control Recruiting nowThe purpose of this study is to assess if preoperative treatment with Lugol's solution prior to thyroidectomy can reduce the surgical complications hypoparathyroidism and laryngeal nerve palsy
Phase: PHASE3 • Sponsor: Jan Calissendorff • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New dialysis filters aim to cut bleeding risk by reducing heparin use
Disease control Recruiting nowChronic kidney disease (CKD) results from the progressive and irreversible destruction of the kidneys. As of December 31, 2018, there were 89,692 people in France undergoing replacement therapy, including 49,271 (55%) on dialysis and 40,421 (45%) with a functioning kidney transpl…
Phase: NA • Sponsor: CHU de Reims • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Can a beta-blocker help a common type of heart failure? new study investigates.
Disease control CompletedBeta-blockers improve clinical outcomes in heart failure and reduced ejection fraction (HFrEF); but not in those with preserved EF. Global longitudinal strain (GLS) is a prognostic factor independent of left ventricular ejection fraction (LVEF). In a retrospective with 1969 patie…
Phase: PHASE4 • Sponsor: Seoul National University Bundang Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could a common blood pressure drug improve major surgery outcomes?
Disease control CompletedHemodynamic instability is frequent during surgery and intraoperative hypotension is associated with excess morbidity and excess mortality in high-risk patients. In major abdominal surgery the incidence of intraoperative hypotension remains high. For the past few years, some tea…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
15,000 patients to reveal hidden heart dangers of Same-Day surgery
Knowledge-focused Recruiting nowThe proportion of noncardiac surgeries performed as same-day surgery is increasing worldwide, with more complex surgeries being performed on higher risk patients in the outpatient setting. Little is known on the risk factors, incidence and prognosis of patients undergoing same-da…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Experimental immune cell therapy takes aim at childhood cancers
Disease control Recruiting nowThis is a phase I dose-escalation study to evaluate the safety of partially human leukocyte antigen (HLA)-matched multi tumor-associated antigen-specific T cell (TAA-T) therapy for patients with high-risk solid tumors due to the presence of refractory, relapsed and/or minimal res…
Phase: PHASE1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo therapy for aggressive lymphoma enters safety testing
Disease control OngoingThis phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed to block a protein called Brut…
Phase: PHASE1 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy targets nerve pain in rare blood cancers
Disease control OngoingIn this research study, is combining a new treatment acalabrutinib with a standard treatment, rituximab or other CD20 antibody, to determine whether this combination is safe and effective for participants with Immunoglobulin (Ig) M monoclonal gammopathy of undetermined significan…
Phase: PHASE2 • Sponsor: Shayna Sarosiek, MD • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Can a mindfulness app rewire Teens' brains to stop overthinking?
Knowledge-focused Recruiting nowA growing body of research implicates rumination as being a transdiagnostic risk factor involved in the development of depression and anxiety in youth. Critically, mindfulness meditation has shown significant promise in targeting rumination, and ultimately improving depressive an…
Phase: NA • Sponsor: Mclean Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Experimental combo for lung cancer shows promise but study cut short
Disease control TerminatedThis is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in subjects with PD-L1-expressing (TPS ≥ 1%), metastatic (Stage IV) or locally advanced squamous or non-squamous NSCLC who have not re…
Phase: PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill hopes to fight Hard-to-Treat cancers
Disease control CompletedThis is a Phase 1/2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and preliminary anti-tumor activity of IPG7236 administered orally as a single agent to patients with advanced solid tumors. The stud…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can kids with cancer stop antibiotics sooner? new trial investigates
Disease control CompletedThis randomised controlled trial will determine the non-inferiority of stopping empiric antibiotics prior to absolute neutrophil count (ANC) recovery (Early Stopping) versus stopping antibiotics upon ANC recovery (Standard of Care/ Late Stopping) , in children with cancer and hig…
Phase: PHASE4 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Lymphoma Patients' vaccine response under scrutiny
Knowledge-focused TerminatedThe specific immune response to SARS-CoV-2 includes a humoral response - specific IgM appearing 5 days after the onset of symptoms while IgG appears after 14 days - and a T lymphocyte component, with specific activated CD8 and CD4 T lymphocytes. Mortality from infection varies g…
Phase: NA • Sponsor: Versailles Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Could a common numbing drug cut opioid use after liver surgery?
Symptom relief CompletedThis is a randomized double blinded placebo-controlled study, conducted in Lund, Sweden. Patients will be randomized in two groups, with a ratio of 1:1. The experimental arm will receive intravenous Lidocaine perioperatively, and the Control arm will receive placebo, i.e. normal …
Phase: PHASE2, PHASE3 • Sponsor: Lund University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
New syringe design tested for common eye disease treatment
Disease control OngoingThe study will compare the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular degeneration, diab…
Phase: PHASE3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can brain scans forecast stroke recovery?
Knowledge-focused Recruiting nowOur study aims to measure metabolic and functional parameters of the infarcted territory by multimodal cerebral MRI in patients diagnosed with unilateral proximal occlusion of the middle cerebral artery and treated by thrombectomy in order to correlate those parameters to clinica…
Phase: NA • Sponsor: Poitiers University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Can learning to cope help kids breathe easier?
Symptom relief CompletedUncontrolled asthma in school-aged children is a significant public health problem. Latino children living in low-income contexts are at increased risk for uncontrolled asthma compared to non-Latino white children, and stress is an unaddressed factor in this disparity. Therefore,…
Phase: NA • Sponsor: Erin M Rodriguez • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC